Aurora Cannabis Inc. (TSE:ACB - Free Report) - Equities research analysts at Roth Capital issued their Q1 2026 EPS estimates for Aurora Cannabis in a report released on Thursday, February 6th. Roth Capital analyst W. Kirk anticipates that the company will earn $0.24 per share for the quarter. The consensus estimate for Aurora Cannabis' current full-year earnings is ($0.22) per share. Roth Capital also issued estimates for Aurora Cannabis' Q2 2026 earnings at $0.03 EPS, Q3 2026 earnings at $0.57 EPS and Q4 2026 earnings at $0.41 EPS.
Several other research firms have also weighed in on ACB. TD Securities upgraded shares of Aurora Cannabis to a "strong-buy" rating in a research note on Thursday, December 12th. ATB Capital dropped their price objective on shares of Aurora Cannabis from C$11.00 to C$8.50 in a report on Tuesday, December 17th. Finally, Atb Cap Markets upgraded Aurora Cannabis from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, February 5th. Three equities research analysts have rated the stock with a hold rating and two have given a strong buy rating to the company. According to data from MarketBeat, Aurora Cannabis presently has a consensus rating of "Moderate Buy" and a consensus price target of C$7.11.
Get Our Latest Stock Analysis on ACB
Aurora Cannabis Trading Down 1.4 %
TSE ACB traded down C$0.13 during trading hours on Friday, hitting C$9.37. 859,911 shares of the company's stock were exchanged, compared to its average volume of 660,273. Aurora Cannabis has a 1-year low of C$3.84 and a 1-year high of C$12.85. The company has a current ratio of 3.76, a quick ratio of 2.48 and a debt-to-equity ratio of 16.95. The stock has a 50-day simple moving average of C$6.18 and a 200 day simple moving average of C$7.18. The firm has a market cap of C$512.16 million, a price-to-earnings ratio of -14.87 and a beta of 2.71.
Aurora Cannabis Company Profile
(
Get Free Report)
Aurora Cannabis, headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Aurora, CanniMed, Daily Special, MedReleaf, and San Rafael '71. Although the company primarily operates in Canada, it has expanded internationally through medical cannabis exporting agreements or cultivation facilities in more than 20 countries.
Featured Articles
Before you consider Aurora Cannabis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aurora Cannabis wasn't on the list.
While Aurora Cannabis currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
